% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sobas:294426,
      author       = {M. A. Sobas and A. T. Turki and A. V. Ramiro and A. H.
                      Sánchez and J. M. Elicegui and T. González and R. A.
                      Melchor and M. Abáigar and L. Tur and D. Dall'Olio and E.
                      Sträng and J. M. Tettero and G. Castellani and A.
                      Benner$^*$ and K. Döhner and C. Thiede and K. H. Metzeler
                      and T. Haferlach and F. Damm$^*$ and R. Ayala and J.
                      Martínez-López and K. I. Mills and J. Sierra and S.
                      Lehmann and M. G. D. Porta and J. Mayer and D. Reinhardt and
                      R. V. Medina and R. Schulze-Rath and M. Barbus and J. M.
                      Hernández-Rivas and B. J. P. Huntly and G. Ossenkoppele and
                      H. Döhner and L. Bullinger$^*$},
      title        = {{O}utcomes with intensive treatment for acute myeloid
                      leukemia: an analysis of two decades of data from the
                      {HARMONY} {A}lliance.},
      journal      = {Haematologica},
      volume       = {110},
      number       = {5},
      issn         = {0390-6078},
      address      = {Pavia},
      publisher    = {Ferrata Storti Foundation},
      reportid     = {DKFZ-2024-02255},
      pages        = {1126-1140},
      year         = {2025},
      note         = {2025 May 1;110(5):1126-1140},
      abstract     = {Since 2017, targeted therapies combined with conventional
                      intensive chemotherapy have started to improve outcome of
                      patients with acute myeloid leukemia (AML). However, even
                      before these innovations outcomes with intensive
                      chemotherapy have improved, which has not yet been
                      extensively studied. Thus, we used a large pan-European
                      multicenter dataset of the HARMONY Alliance to evaluate
                      treatment-time dependent outcomes over two decades. In 5359
                      AML patients, we compared the impact of intensive induction
                      therapy on outcome over four consecutive 5-year calendar
                      periods from 1997 to 2016. During that time, the 5- year
                      survival of AML patients improved significantly, also across
                      different genetic risk groups. In particular, the 60-day
                      mortality rate has dropped from $13.0\%$ to $4.7\%$ over
                      time. The independent effect of calendar periods on outcome
                      was confirmed in multivariate models. Improvements were
                      documented both for patients.},
      cin          = {C060 / BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)BE01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39506894},
      doi          = {10.3324/haematol.2024.285805},
      url          = {https://inrepo02.dkfz.de/record/294426},
}